Evaluation of Genetic and Biochemical Factors in Patients with Acute Coronary Syndrome
##plugins.themes.bootstrap3.article.details##
Introduction: The cardiovascular diseases are the principal cause of death worldwide and a public health problem in Colombia. From the cardiac related illnesses, the most frequent is the Acute Coronary Syndrome (ACS). One of its risk factor is high plasma levels of homocysteine. The enzyme Paraoxonase 1 (PON1) hydrolyzes Homocysteine-thiolactone, producing homocysteine, avoiding damage to endothelium related to Homocysteine-thiolactone. Two genetic variants in PON1 gene have been associated with levels of homocysteine and acute coronary syndrome. Objective: to determine the relationship between the polymorphisms Q192R and L55M from gene PON1 and the levels of homocysteine, HDL, apo A-1 and the enzymatic activity of Paraoxonase I in patients who suffered acute coronary syndrome. Methods: sixteen unrelated patients with Acute Coronary Syndrome (ACS) and sixteen healthy controls were enrolled. The paraoxonase activity, levels of homocysteine, HDL and apo A-1 were assessed. The DNA polymorphism analysis was performed using Polymerase Chain Reaction (PCR) and digestion with restriction enzymes. Results: levels of homocysteine are higher in cases (p<0.0001) and the genotypes 192RR and QR are associated with higher levels of homocysteine (p=0.0234). Conclusion: polymorphisms in PON1 gene could be related to homocysteine levels in Acute Coronary Syndrome patients.
2. Ministerio de Salud y Protección Social, Colciencias. Guía práctica clínica para el síndrome coronario agudo [internet]. Bogotá; 2013. Available from: https://www.medicosgeneralescolombianos.com/images/Guias_2013/gpc_17prof_sal_sca.pdf
3. Secretaría de Salud. Guía de práctica clínica diagnóstico, estratificación y tratamiento de pacientes con síndrome coronario agudo sin elevación ST. México; 2010.
4. Porth CM. Fisiopatología: salud-enfermedad. Un enfoque conceptual. Bogotá: Editorial Médica Panamericana; 2006.
5. Rosales M de los AA. Guía para diagnóstico y tratamiento de las personas con síndrome coronario agudo. San José : Editorial Nacional de Salud y Seguridad Social; 2013.
6. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009;30:6-15.
7. Perła-Kaján J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism. Amino Acids. 2012;43:1405-17.
8. Companioni O, Rodríguez Esparragón F, Fernández-Aceituno AM, Rodríguez Pérez JC. Genetic variants, cardiovascular risk and genome-wide association studies. Rev Esp Cardiol. 2011;64:509-14.
9. Bermúdez M, Briceño I, Gil F, Bernal J. Homocisteína y polimorfismos de cistationina β sintasa y metilentetrahidrofolato reductasa en población sana de Colombia. Colomb Med. 37:46-52.
10. Prieto K, García-Robles R, Bernal J, Bermúdez M. Análisis descriptivo de los niveles de homocisteína, polimorfismos C699T, C1080T y 844Ins68pb de la CBS, C677T de la MTHFR y otros factores de riesgo cardiovascular en una población colombiana con síndrome coronario agudo. Univ Med. 2015;50(4):322-34.
11. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
12. Instituto Nacional de Salud. Boletín Observatorio Nacional de Salud [internet]. 2013 dic 9;(1). Disponible en: http://www.ins.gov.co/lineas-de-accion/ons/boletin%201/boletin_web_ONS/boletin_01_ONS.pdf
13. Santilli F, Davì G, Patrono C. Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. Vascul. Pharmacol. 2016;78:1-9.
14. Bawaskar HS, Bawaskar P himmatrao, Bawaskar PH. Homocysteine and cardiovascular system. Int Res J Pharm Sci. 2015;1-7.
15. Kresanov P, Vasankari T, Ahotupa M, Kaikkonen J, Hutri-Kähönen N, Juonala M, et al. Paraoxonase-1 and oxidized lipoprotein lipids: The cardiovascular risk in young finns study. Atherosclerosis. 2015;241:502-6.
16. Koubaa N, Nakbi A, Hammami S, Attia N, Mehri S, Ben Hamda K, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem. 2009;42:771-6.
17. Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015;439:5-13.
18. Kallel A, Sediri Y, Sbaï MH, Mourali MS, Feki M, Elasmi M, et al. The paraoxonase L55M and Q192R gene polymorphisms and myocardial infarction in a Tunisian population. Clin Biochem. 2010;43:1461-3.
19. Lakshmy R, Ahmad D, Abraham RA, Sharma M, Vemparala K, Das S, et al. Paraoxonase gene Q192R & L55M polymorphisms in Indians with acute myocardial infarction & association with oxidized low density lipoprotein. Indian J Med Res. 2010;131:522-9.
20. Wang M, Lang X, Zou L, Huang S, Xu Z. Four genetic polymorphisms of paraoxonase gene and risk of coronary heart disease: A meta-analysis based on 88 case-control studies. Atherosclerosis. 2011;214:377-85.
21. Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, Kastelein JJ, Grobbee DE, et al. Paraoxonase variants relate to 10-year risk in coronary artery disease: Impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol. J Am Colleg Cardiol. 2009;54:1238-45.
22. Roever L, Reis P. Screening for peripheral arterial disease: An update. J Vasc Med Surg [internet]. 2015;3:197. Available from: https://www.esciencecentral.org/journals/screening-for-peripheral-arterial-disease-an-update-2329-6925-1000197.php?aid=54124